Pharmaceuticals Companies By Pb Ratio

Price To Book
Price To BookEfficiencyMarket RiskExp Return
1AMRX Amneal Pharmaceuticals Class
86.1
 0.13 
 3.05 
 0.40 
2LLY Eli Lilly and
66.34
 0.16 
 1.57 
 0.25 
3NVO Novo Nordisk AS
41.26
 0.11 
 1.37 
 0.15 
4SCLX Scilex Holding
28.85
(0.02)
 6.95 
(0.17)
5PHAT Phathom Pharmaceuticals
25.37
 0.10 
 5.09 
 0.52 
6MRNS Marinus Pharmaceuticals
24.57
(0.10)
 11.44 
(1.15)
7OPTN OptiNose
24.26
(0.13)
 5.54 
(0.74)
8LQDA Liquidia Technologies
22.43
 0.02 
 3.19 
 0.07 
9BHC Bausch Health Companies
18.78
(0.22)
 2.56 
(0.56)
10WVE Wave Life Sciences
17.9
(0.04)
 4.14 
(0.16)
11AXSM Axsome Therapeutics
17.15
 0.04 
 2.58 
 0.10 
12EOLS Evolus Inc
17.05
(0.09)
 2.00 
(0.17)
13AVDL Avadel Pharmaceuticals PLC
16.52
(0.02)
 2.69 
(0.05)
14ELTX Elicio Therapeutics
15.92
 0.12 
 6.26 
 0.75 
15SEEL Seelos Therapeutics
15.1
(0.40)
 7.82 
(3.10)
16VRCA Verrica Pharmaceuticals
14.83
 0.20 
 4.09 
 0.80 
17ZTS Zoetis Inc
13.71
(0.02)
 1.83 
(0.04)
18OCUL Ocular Therapeutix
13.03
(0.17)
 5.32 
(0.93)
19RVNC Revance
12.3
(0.24)
 5.01 
(1.20)
20ITCI Intracellular Th
10.78
 0.04 
 3.56 
 0.13 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities. Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.